Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.85 |
| ▸ | GBA1 | P04062 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.56 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84802 | 1.00 | FUCA1 (0.85) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL562632 | 1.00 | FUCA1 (0.85) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL20017877 | 1.00 | FUCA1 (0.85) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL5155562 | 1.00 | FUCA1 (0.85) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| Hydrochloric Acid SCHEMBL10840201 | 0.98 | FUCA1 (0.81) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL15599205 | 0.92 | FUCA1 (0.92) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL7637770 | 0.92 | FUCA1 (1.00) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL15599027 | 0.92 | FUCA1 (0.92) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL17181666 | 0.92 | FUCA1 (0.92) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL15599028 | 0.92 | FUCA1 (0.92) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493628-A | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2021-10-12 | — | — | CN | claimed |
| CN-113122053-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| US-20180009841-A1 | METHOD FOR PREPARING NANOPRECIPITATES OF LOW MOLECULAR WEIGHT PEPTIDE OR PROTEIN | CARLINA TECHNOLOGIES (FR) | 2018-01-11 | — | — | US | claimed |
| EP-2990033-A1 | Process of nanoprecipitation of proteins and peptides with low molecular weight | Carlina Technologies (FR) | 2016-03-02 | — | — | EP | claimed |
| EP-3275448-B1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLES | KYOWA KIRIN CO LTD (JP) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025099451-A1 | NEW COMPOUNDS AND METHODS | Transition Bio Limited (GB) | 2025-05-15 | — | — | WO | disclosed |
| CN-114507215-B | Compound serving as PAK4 kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
| CN-113493628-B | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-11633365-B2 | Nucleic acid-containing lipid nanoparticle | KYOWA KIRIN CO., LTD. (JP) | 2023-04-25 | — | — | US | disclosed |
| US-11566029-B2 | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | IP2IPO INNOVATIONS LIMITED (GB) | 2023-01-31 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-6573377-B1 | Antitumor agent capable of showing its efficacy even against 5- FU drug resistant tumors | DAIICHI PHARMACEUTICALS CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1103551-A1 | PYRAZOLE DERIVATIVES AND SALTS THEREOF | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0973738-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2000-01-26 | — | — | EP | disclosed |
| US-5952363-A | Pyrrolidine compounds useful in the treatment of diabetes | NOVO NORDISK A/S (DK) | 1999-09-14 | — | — | US | disclosed |
| WO-1998040353-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-09-17 | — | — | WO | disclosed |
| US-5585500-A | Method of producing optically active pyrrolidines with high enantiomeric purity | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1996-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633365-B2 | Nucleic acid-containing lipid nanoparticle | LIPA, LIPC, PNLIP | FUCA1 906/4885GBA1 128/4885SIGMAR1 2946/4885 |
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | FUCA1 1734/4885GBA1 111/4885SIGMAR1 963/4885 |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, TK1 | FUCA1 2462/4885GBA1 202/4885SIGMAR1 1679/4885 |
| US-11566029-B2 | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | CDK10, CDK1, CDK20 | FUCA1 3993/4885GBA1 4215/4885SIGMAR1 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.